Showing 321 - 340 results of 115,446 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( a ((non decrease) OR (nn decrease)) ))', query time: 1.58s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324

    Data Sheet 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf by Wei Gong (112494)

    Published 2025
    “…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
  5. 325

    Supplementary file 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf by Wei Gong (112494)

    Published 2025
    “…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  13. 333
  14. 334
  15. 335
  16. 336
  17. 337

    DataSheet2_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.pdf by Sunil Veeravalli (5074115)

    Published 2022
    “…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
  18. 338

    DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF by Sunil Veeravalli (5074115)

    Published 2022
    “…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
  19. 339
  20. 340